,12 For example, a prespecified analysis of the pivotal ENGAGE AF-TIMI (Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study) 48 trial—a study which looked at patients with nonvalvular AF treated with edoxaban vs VKA—demonstrated that patients aged ≥75 years had a significantly lower MB event rate with edoxaban 30 mg vs warfarin.11 This evidence concerns the gene TNXA and atrial fibrillation.